P01 Modulation of the µ-opioid pathway for the treatment of pruritus: a systematic review of 1146 patients across dermatological and systemic conditions
Clicks: 1
ID: 318436
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #266 of 304 articles by views in the british journal of dermatology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 304 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Introduction and aims Pruritus is a debilitating symptom across dermatological and systemic diseases, and conventional therapies often provide incomplete relief. The µ-opioid receptor pathway is a key regulator of itch. A range of µ-pathway-modulating agents are used off-label for refractory pruritus. This review aimed to systematically evaluate the efficacy, safety, and real-world use of µ-opioid pathway modulators for pruritus of dermatological and systemic origin. Methods We conducted a systematic review following PRISMA guidelines (PROSPERO CRD420251207101), with a comprehensive search of four databases. Results were narratively synthesized owing to heterogeneity. Results Of 3274 records identified, 69 studies met inclusion criteria: 14 randomized controlled trials (RCTs) (n = 795) and 55 nonrandomized studies (n = 351). Five RCTs evaluated dermatological conditions (atopic dermatitis, prurigo nodularis, chronic urticaria, and lichen planopilaris), while 9 RCTs evaluated systemic pruritus, predominantly cholestatic pruritus and uraemic pruritus. RCTs (1980–2023) assessed oral or topical naltrexone, intravenous naloxone, nalmefene and nalbuphine extended release. Most RCTs demonstrated clinically meaningful reductions in pruritus severity, measured using validated itch scales [visual analogue scale, numeric rating scale (NRS) or worst itch NRS], with the strongest evidence observed in atopic dermatitis, cholestatic pruritus, and uraemic pruritus. Nonrandomized studies (1979–2024) included 199 dermatological and 152 systemic cases, reporting improvement across conditions such as Hailey–Hailey disease, Darier disease, psoriasis, dermatomyositis, chronic pruritus, postburn pruritus, systemic sclerosis and cholestatic disease. Adverse events were mostly mild and tolerated. Conclusions µ-Opioid pathway modulators demonstrate promising efficacy with acceptable short-term safety across a broad spectrum of pruritic conditions. Evidence from randomized trials is strongest for naltrexone and nalmefene in cholestatic pruritus, naltrexone in atopic dermatitis and chronic urticaria, and nalbuphine in uraemic pruritus. In addition, signals of benefit from nonrandomized and real-world studies suggest potential utility across a wider range of dermatological and systemic conditions. Larger, high-quality RCTs are needed to define optimal dosing and support further clinical translation.
| Reference Key |
openalex_W7165669542
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Khalid M A Ahmed, Amro Abu Suleiman, Alaa I. Al-Najdawi, Dina Abdulkader, A AHMED, E. W. HORTON |
| Journal | the british journal of dermatology |
| Year | 2026 |
| DOI |
10.1093/bjd/ljag151.042
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.